Table 4.
Literature summary of the blood brain barrier (BBB) penetrating nanoparticles (NPs) for Alzheimer’s disease (AD), Parkinson’s disease (PD, and stroke applications.
| S. No. | Nanoplatforms (NF) | Disease Model | Therapeutic Strategy | Ref. |
|---|---|---|---|---|
| 1 | HMON-abAβ40 | AD | Aβ1-40 peptide, MR imaging | [125] |
| 2 | Liposome NPs | AD | Carrier, MR, and NIRF imaging | [126] |
| 3 | GSH-Au NPs | AD | inhibition of Aβ42 | [127] |
| 4 | PEG–PLGA NPs | AD | Memantine delivery | [128] |
| 5 | B6-SA-Se NPs | AD | inhibition of Aβ42 | [115] |
| 6 | MCPZFS NP | AD | inhibition of Aβ42 | [117] |
| 7 | Gal-NP@siRNA | AD | silencing of BACE1 | [118] |
| 8 | DP-PLGA NPs | PD | Dopamine delivery | [122] |
| 9 | PLGA NPs | PD | Ropinirole delivery | [123] |
| 10 | B6ME-NPs | PD | EGCG delivery, MR imaging | [124] |
| 11 | Tf-TMD-PLGA-NP | PD | Tramadol delivery | [129] |
| 12 | PS 80-modified-CPC | PD | curcumin nanocarrier | [130] |
| 13 | Lf-BP-Pae | PD | Paeoniflorin (Pae) delivery | [131] |
| 14 | Dex-IO NPs | PD | Improve the human MSCs (hMSCs) | [132] |
| 15 | RvD2-HVs | Stroke | Decrease TNF-α and alleviate inflammation responses | [133] |
| 16 | pSV-HO-1/R3V6-Dexa | Stroke | Dexamethasone drug delivery | [134] |
| 17 | E-A/P-CeO2 | Stroke | ROS scavenging ability | [135] |
| 18 | Mn3O4@nanoerythrocyte-T7 (MNET) | Stroke | scavenged free radical and oxygen supply | [136] |
| 19 | Chitosan NPs | Stroke | basic fibroblast growth factor (bFGF) and a small peptide inhibitor of caspase-3 | [137] |
| 20 | Protein-Carbon Dot Nanohybrid | Stroke | early detection of BBB damage and thrombolytic agent distribution | [138] |
Abbreviations: hollow manganese oxide nanoparticles (HMON), antibody of Aβ1-40 peptide (abAβ40), glutathione (GSH), sialic acid (SA), selenium (Se), zwitterion poly(carboxybetaine) (PCB)-based nanoparticle (MCPZFS NP), Small interfering RNAs (siRNAs), dual-target traceable nanodrug (B6ME-NPs), Tramadol (TMD), curcumin (CPC), lactoferrin (Lf), Paeoniflorin (Pae), black phosphorus nanosheets (BP), Dextran (Dex), Resolvin D2 (RvD2), heme oxygenase-1 (HO-1), Dexamethasone (Dexa), R3V6 peptide (R3V6), Cerium dioxide (CeO2), Angiopep-2 and poly(ethylene glycol) (E-A/P), and manganese oxide (Mn3O4).